Inventiva 在美国 IPO 中筹集了 $140M，用于资助肝脏试验和药物上市，股票将于 11 月 13 日开始在纳斯达克交易。 Inventiva raises $140M in U.S. IPO to fund liver trial and drug launch, with shares trading on Nasdaq starting Nov. 13.

Inventiva 已将 3896 万股美国存托股票的美国公开发行定价为每股 3.85 美元，筹集了约 1.401 亿美元的净收益，承销商可以选择购买更多股票，这可能会将收益增加到 1.612 亿美元。 Inventiva has priced a U.S. public offering of 38.96 million American Depositary Shares at $3.85 each, raising about $140.1 million in net proceeds, with an option for underwriters to buy more shares potentially increasing proceeds to $161.2 million. 这项资助其第三阶段MASH试验和商业化的活动将于2025年11月17日结束。 The offering, which supports its Phase 3 MASH trial and commercialization, is set to close on November 17, 2025. 11月13日暂时停止了该公司对欧洲第二巴黎的普通股份交易,以便利该交易,预计当天晚些时候将恢复,与纳斯达克ADS开始交易的时间一致。 Trading in the company’s ordinary shares on Euronext Paris was temporarily halted on November 13 to facilitate the offering and is expected to resume later that day, aligning with the start of ADS trading on Nasdaq.